Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
Abstract
BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-2437
Entities
People
- Amish J. Patel
- Chung-ping Liao
- Jonathan M Cooper
- Juan Mo
- Kun Chen
- Lu Q Le
- Yong Wang
- Zhiguo Chen
Organizations
- National Institutes of Health
- United States Department of Defense
- University of Texas at Austin